Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized controlled study of CapeOX after radical resection in elderly patients with colorectal cancer
ChiCTR-TRC-11001603Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of capecitabine and oxaliplatin in colorectal cancer (CRC) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Safety, Survival and 1 more. Started Jan 2011; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR-TRC-11001603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001603.